Benitec Biopharma Reports Director Changes and Officer Compensation Updates
Ticker: BNTC · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1808898
| Field | Detail |
|---|---|
| Company | Benitec Biopharma INC. (BNTC) |
| Form Type | 8-K |
| Filed Date | Dec 13, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 B, $500,000, $12.18, $667,000, $415,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Board shakeup and pay adjustments at Benitec Biopharma.
AI Summary
On December 9, 2024, Benitec Biopharma Inc. reported a change in its board of directors and executive compensation arrangements. The filing indicates a departure of directors and the election of new officers, alongside adjustments to compensatory arrangements for certain key personnel.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial priorities, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding the company's future direction and stability.
Key Players & Entities
- Benitec Biopharma Inc. (company) — Registrant
- December 9, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Hayward, California (location) — Principal Executive Offices
FAQ
What specific roles have been affected by the director departures and officer appointments?
The filing indicates a departure of directors and the election of certain officers, but does not specify the exact roles that have changed.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 9, 2024.
What is the principal executive office address for Benitec Biopharma Inc.?
The principal executive offices are located at 3940 Trust Way, Hayward, California, 94545.
What is the SIC code for Benitec Biopharma Inc.?
The Standard Industrial Classification (SIC) code for Benitec Biopharma Inc. is 2834, Pharmaceutical Preparations.
What is the filing date of this 8-K report?
This 8-K report was filed as of December 13, 2024.
Filing Stats: 862 words · 3 min read · ~3 pages · Grade level 13.3 · Accepted 2024-12-13 16:15:52
Key Financial Figures
- $0.0001 B — ich registered Common Stock, par value $0.0001 BNTC The Nasdaq Stock Market LLC Indic
- $500,000 — e Mukadam will receive a base salary of $500,000 and a target annual bonus of 40% of bas
- $12.18 — ns were granted at an exercise price of $12.18 per share, which equals the closing pri
- $667,000 — salaries of Dr. Banks and Ms. Boston to $667,000 and $415,000, respectively, each adjust
- $415,000 — r. Banks and Ms. Boston to $667,000 and $415,000, respectively, each adjustment being ef
Filing Documents
- d853112d8k.htm (8-K) — 26KB
- 0001193125-24-278529.txt ( ) — 142KB
- bntc-20241209.xsd (EX-101.SCH) — 3KB
- bntc-20241209_lab.xml (EX-101.LAB) — 17KB
- bntc-20241209_pre.xml (EX-101.PRE) — 11KB
- d853112d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BENITEC BIOPHARMA INC. Date: December 13, 2024 By: /s/ Jerel A. Banks Name: Jerel A. Banks Title: Chief Executive Officer